Our Business
Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the delivery, activity and safety of proven pharmaceutical and personal care products (including nutraceuticals and cosmeceuticals).
Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and Phosphagenics' ADR's (PPGNY) are traded on the OTCQX in the US.
Breaking News
2 September 2010
PHOSPHAGENICS EXERCISES OPTION TO LICENCE AOD9604 TO DEVELOP TOPICAL CELLULITE PRODUCT
- Cosmeceutical with potential short timeframe to market
- TPM™ technology superior in delivering active ingredients providing greater results
- Human testing scheduled for late 2010 - early 2011
Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has exercised its option to licence the Calzada Limited (ASX: CZD) (formerly Metabolic Pharmaceuticals Limited) patented compound, AOD9604, for use as a cosmeceutical product aimed at reducing the appearance of cellulite and subcutaneous fat.
24 August 2010
PHOSPHAGENICS APPOINTS THREE NEW NON-EXECUTIVE DIRECTORS TO BOOST ITS COMMERCIAL TRANSFORMATION
- Stuart James – former CEO & Managing Director of Mayne Pharma
- Sandra Webb – Director of Ground Zero Pharmaceuticals
- Don Clarke – Partner, Minter Ellison, Deputy Chair of Webjet & Director Circadian Technologies
Phosphagenics Limited has appointed Mr Stuart James, Dr Sandra Webb and Mr Don Clarke as Non-Executive Directors to formulate and facilitate the implementation of strategies to commercialise the company’s research and development pipeline.
All new Directors have senior commercial experience and align with Phosphagenics’ transition from product development to product distribution and sales.
Read our latest news: NEWSLETTER - JULY 2010
To view releases in full please click here
